Recurrent or metastatic cervical cancer
Clinical trials for Recurrent or metastatic cervical cancer explained in plain language.
Never miss a new study
Get alerted when new Recurrent or metastatic cervical cancer trials appear
Sign up with your email to follow new studies for Recurrent or metastatic cervical cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune cells from your own tumor could fight cervical cancer
Disease control Recruiting nowThis study tests a new treatment called GT101, which uses immune cells taken from a patient's own tumor to fight recurrent or metastatic cervical cancer. About 83 adults will receive either GT101 or a standard chemotherapy drug. The goal is to see if the cell therapy can delay ca…
Matched conditions: RECURRENT OR METASTATIC CERVICAL CANCER
Phase 2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Triple-Drug cocktail takes on recurrent gynecologic cancers
Disease control Recruiting nowThis Phase II study tests a combination of three drugs—BL-B01D1, pembrolizumab, and possibly bevacizumab—in people whose cervical or endometrial cancer has come back or spread. The goal is to see if the combo shrinks tumors and to find the best dose. About 96 adults aged 18–75 wi…
Matched conditions: RECURRENT OR METASTATIC CERVICAL CANCER
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for Hard-to-Treat cervical cancer? drug trial targets HER2
Disease control Recruiting nowThis Phase 2 trial is testing a drug called SHR-A1811 in 60 women with HER2-expressing cervical cancer that has spread or returned after standard treatments. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal is to see …
Matched conditions: RECURRENT OR METASTATIC CERVICAL CANCER
Phase 2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New study monitors eye health in cervical cancer drug TIVDAK
Symptom relief Recruiting nowThis study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every 3 weeks and undergo regular eye exams before, during, and after treatment…
Matched conditions: RECURRENT OR METASTATIC CERVICAL CANCER
Phase 4 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC